Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - PubMed (original) (raw)
Clinical Trial
. 2019 Nov 1;30(11):1821-1830.
doi: 10.1093/annonc/mdz291.
X V Wang 2, V Makker 3, S-W Luoh 4, E P Mitchell 5, J A Zwiebel 6, E Sharon 7, R J Gray 8, S Li 8, L M McShane 9, L V Rubinstein 10, D Patton 11, P M Williams 12, S R Hamilton 13, B A Conley 14, C L Arteaga 15, L N Harris 14, P J O'Dwyer 16, A P Chen 17, K T Flaherty 18
Affiliations
- PMID: 31504139
- PMCID: PMC6927318
- DOI: 10.1093/annonc/mdz291
Clinical Trial
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri et al. Ann Oncol. 2019.
Erratum in
- Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Jhaveri KL, et al. Ann Oncol. 2021 Aug;32(8):1068. doi: 10.1016/j.annonc.2021.05.797. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34099371 Free PMC article. No abstract available.
Abstract
Background: The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors.
Methods: Eligible patients had HER2 amplification at a copy number (CN) >7 based on targeted next-generation sequencing (NGS) with a custom Oncomine AmpliSeq™ (ThermoFisher Scientific) panel. Patients with prior trastuzumab, pertuzumab or T-DM1 treatment were excluded. Patients received T-DM1 at 3.6 mg/kg i.v. every 3 weeks until toxicity or disease progression. Tumor assessments occurred every three cycles. The primary end point was centrally assessed objective response rate (ORR). Exploratory end points included correlating response with HER2 CN by NGS. The impact of co-occurring genomic alterations and PTEN loss by immunohistochemistry were also assessed.
Results: Thirty-eight patients were enrolled and 36 included in efficacy analysis. Median prior therapies in the metastatic setting was 3 (range 0-9; unknown in one patient). Median HER2 CN was 17 (range 7-139). Partial responses were observed in two (5.6%) patients: one mucoepidermoid carcinoma of parotid gland and one parotid gland squamous cell cancer. Seventeen patients (47%) had stable disease including 8/10 (80%) with ovarian and uterine carcinomas, with median duration of 4.6 months. The 6-month progression-free survival rate was 23.6% [90% confidence interval 14.2% to 39.2%]. Common toxicities included fatigue, anemia, fever and thrombocytopenia with no new safety signals. There was a trend for tumor shrinkage with higher levels of gene CN as determined by the NGS assay.
Conclusion: T-DM1 was well tolerated. While this subprotocol did not meet the primary end point for ORR in this heavily pre-treated diverse patient population, clinical activity was seen in salivary gland tumors warranting further study in this tumor type in dedicated trials.
Keywords: HER2-amplified; NCI-MATCH; NGS; T-DM1.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
Figure 1.
ERBB2 amplification frequency: all tumors excluding breast and gastric/gastroesophageal junction tumors. This plot includes solid tumors (467/28 106 samples and 442/25 637 patients) with a minimum of 50 sequenced tumors and ERBB2 amplification > 0% using MSK-IMPACT assay. The numbers in the parentheses are the total number of sequenced tumors. (cBioPortal.org).
Figure 2.
Consort diagram.
Figure 3.
(A) Efficacy: Best% change from baseline (n = 28). Four patients had PD based on new lesions but data for the target lesions are not available so not included in this plot. (B) Treatment Duration in patients who achieved SD or PR. (C) Kaplan–Meier curve for progression-free survival. GYN, gynecological; CI, confidence interval; GI, gastrointestinal.
Figure 4.
Correlation of best % change by ERBB2 copy number gain (n = 28). PR, partial response; SD, stable disease; PD, progressive disease.
Figure 5.
Co-occurring genomic alterations with HER2 amplification using the NCI-MATCH assay color coded by variant type (left): copy number variant (purple), single nucleotide variant (red), indel (pink) and number of variants (top) for each eligible patient along with information regarding histology and best response on treatment (bottom): partial response (PR), stable disease (SD), progression of disease (PD), unevaluable (UE).
Similar articles
- Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS, Cook MM, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Al Rabadi LS, et al. BMC Cancer. 2021 Oct 27;21(1):1150. doi: 10.1186/s12885-021-08894-2. BMC Cancer. 2021. PMID: 34706686 Free PMC article. - Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, Tricoli JV, Conley BA, Harris LN, Arteaga CL, O'Dwyer PJ, Chen AP, Flaherty KT. Connolly RM, et al. Clin Cancer Res. 2024 Apr 1;30(7):1273-1280. doi: 10.1158/1078-0432.CCR-23-0633. Clin Cancer Res. 2024. PMID: 38433347 Free PMC article. Clinical Trial. - Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article. - HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD, Miles D, Tsui CK, Zong Y. Pegram MD, et al. Clin Cancer Res. 2020 Feb 15;26(4):775-786. doi: 10.1158/1078-0432.CCR-18-1976. Epub 2019 Oct 3. Clin Cancer Res. 2020. PMID: 31582515 Review. - Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, Sotiriou C, Jamieson SMF. Hunter FW, et al. Br J Cancer. 2020 Mar;122(5):603-612. doi: 10.1038/s41416-019-0635-y. Epub 2019 Dec 16. Br J Cancer. 2020. PMID: 31839676 Free PMC article. Review.
Cited by
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.
Quaquarini E, Grillo F, Gervaso L, Arpa G, Fazio N, Vanoli A, Parente P. Quaquarini E, et al. Cancers (Basel). 2024 Sep 13;16(18):3145. doi: 10.3390/cancers16183145. Cancers (Basel). 2024. PMID: 39335117 Free PMC article. Review. - Identification of key genes and pathways involved in T-DM1-resistance in OE-19 esophageal cancer cells through bioinformatics analysis.
Yazdani F, Mottaghi-Dastjerdi N, Shahbazi B, Ahmadi K, Ghorbani A, Soltany-Rezaee-Rad M, Montazeri H, Khoshdel F, Guzzi PH. Yazdani F, et al. Heliyon. 2024 Sep 6;10(18):e37451. doi: 10.1016/j.heliyon.2024.e37451. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309859 Free PMC article. - A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
Thavaneswaran S, Lin F, Grady JP, Espinoza D, Huang ML, Chinchen S, Sebastian L, Kansara M, Mersiades T, Lee CK, Desai J, Grimison P, Brown M, Millward M, Harrup R, O'Byrne K, Nagrial A, Craft P, Simes J, Joshua AM, Thomas DM. Thavaneswaran S, et al. NPJ Precis Oncol. 2024 Sep 9;8(1):195. doi: 10.1038/s41698-024-00698-4. NPJ Precis Oncol. 2024. PMID: 39251683 Free PMC article. - Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.
Kim M, Shim HS, Kim S, Lee IH, Kim J, Yoon S, Kim HD, Park I, Jeong JH, Yoo C, Cheon J, Kim IH, Lee J, Hong SH, Park S, Jung HA, Kim JW, Kim HJ, Cha Y, Lim SM, Kim HS, Lee CK, Kim JH, Chun SH, Yun J, Park SY, Lee HS, Cho YM, Nam SJ, Na K, Yoon SO, Lee A, Jang KT, Yun H, Lee S, Kim JH, Kim WS. Kim M, et al. J Pathol Transl Med. 2024 Jul;58(4):147-164. doi: 10.4132/jptm.2023.11.01. Epub 2024 Jan 10. J Pathol Transl Med. 2024. PMID: 39026440 Free PMC article. Review. - Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN, Chung YS, Park E, Lee ST, Lee JY. Kim YN, et al. Sci Rep. 2024 Apr 5;14(1):7992. doi: 10.1038/s41598-024-57515-y. Sci Rep. 2024. PMID: 38580676 Free PMC article.
References
- Slamon DJ, Clark GM, Wong SG. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177–182. - PubMed
- Slamon DJ, Godolphin W, Jones LA. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244(4905): 707–712. - PubMed
- Wolff AC, Hammond ME, Hicks DG. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JCO 2013; 31(31): 3997–4013. - PubMed
- Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687–697. - PubMed
- Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783–792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UG1 CA233290/CA/NCI NIH HHS/United States
- UG1 CA233329/CA/NCI NIH HHS/United States
- U24 CA196172/CA/NCI NIH HHS/United States
- UG1 CA233341/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- UG1 CA233302/CA/NCI NIH HHS/United States
- P30 CA142543/CA/NCI NIH HHS/United States
- UG1 CA233180/CA/NCI NIH HHS/United States
- U10 CA180820/CA/NCI NIH HHS/United States
- U10 CA180794/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous